A significant drug production facility has been officially inaugurated in Afghanistan's southern province of Kandahar, marking a major milestone for the nation's pharmaceutical industry. The newly unveiled Snow Pharma pharmaceutical factory is hailed as one of the largest drug manufacturing plants in Afghanistan to date.

With a remarkable capacity to produce 5.8 million tablets, 2 million capsules, and 60 thousand bottles of syrup in just 8 hours, the Snow Pharma facility is poised to play a pivotal role in meeting the country's medicinal demands. It is estimated that this factory's operations will fulfill approximately 25 percent of Afghanistan's pharmaceutical needs.

Afghanistan currently heavily relies on importing drugs from neighboring countries and distant sources. However, the establishment of Snow Pharma signals a promising shift towards achieving greater self-sufficiency in meeting the nation's healthcare requirements.

Mohammad Sayed Sediq, the head of Snow Pharma, revealed that the construction of this state-of-the-art drug manufacturing facility required a substantial investment of $50 million. The project was made possible through the collaborative efforts of 71 stakeholders who joined forces to build the factory in Kandahar, located in the country's southern region.

The development and installation of cutting-edge equipment within the Snow Pharma facility took a remarkable six years to complete, highlighting the meticulous attention to detail and commitment to quality. Mr. Sediq emphasized that all Snow Pharma products adhere to the stringent standards set by the World Health Organization (WHO), ensuring the highest level of safety and efficacy.

The distinguished inauguration ceremony of the factory was graced by the presence of high-ranking officials from the Islamic Emirate of Afghanistan in Kandahar, underscoring the significance of this momentous achievement.

The establishment of Snow Pharma in Kandahar represents a significant stride towards reducing Afghanistan's dependence on drug imports. This venture holds immense potential for the country's pharmaceutical industry, marking a remarkable milestone in its journey towards achieving self-sufficiency in meeting the vital healthcare needs of its citizens. (ILKHA)